<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345523</url>
  </required_header>
  <id_info>
    <org_study_id>ConPlas-19</org_study_id>
    <nct_id>NCT04345523</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients</brief_title>
  <acronym>ConPlas-19</acronym>
  <official_title>Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristina Avendaño Solá</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 278 patients are planned.

      All patients will be in an early-stage of COVID-19. They must be adults and hospitalized.

      In this study, all participating patients will receive the standard treatment provided
      according to the current treatment protocols for coronavirus disease. In addition to this
      treatment, each patient will be randomly assigned to receive additional treatment with
      convalescent plasma transfusion (CP; blood plasma from patients who have been cured of
      coronavirus), or continue with standard treatment but without adding transfusion.

      50% of the chances of additional treatment with CP, and 50% of the chances of receiving only
      the standard treatment for coronavirus.

      The duration of the study shall be one month from the assignment of the treatment.

      The patient and the doctor will know the treatment assigned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, randomized, clinical trial with two arms to study the efficacy and safety of
      passive immunotherapy with CP compared to a control of standard of care (SOC).

      All trial participants will receive SOC:

        -  Treatment arm: Pathogen-reduced CP from patients recovered from COVID-19, whom, for the
           purpose of this trial, are herein designated as donors.

        -  Control arm: SOC for COVID-19.

      Randomization among the two arms will be 1:1 and will be stratified per center. Of note, in
      the current status of a worldwide pandemic for which we have no approved vaccines or drugs,
      for the purpose of this trial SOC would also accept any drugs that are being used in clinical
      practice (e.g. lopinavir/ritonavir; darunavir/cobicistat; hydroxy/chloroquine, tocilizumab,
      etc.), other than those used as part of another clinical trial.

      The study is planned with a sequential design. Interim analyses: comprehensive safety data
      monitoring analyses will be conducted when 20%, 40%, 60% and 80% of patients, or at the
      discretionary DSMB criteria when needed. A DSMB charter will be set before the trial
      initiation where criteria for prematurely stopping the trial due to safety issues will be
      set. Interim analyses will be predefined upfront based on the DSMB recommendations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 ratio for CP: Control arm. Also, approximately 140-200 CP donors.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Category Changes in Ordinal Scale</measure>
    <time_frame>15 days</time_frame>
    <description>Proportion of patients in categories 5, 6 or 7 of the 7-point ordinal scale at day 15
Ordinal scale:
Not hospitalized, no limitations on activities.
Not hospitalized, limitation on activities.
Hospitalized, not requiring supplemental oxygen.
Hospitalized, requiring supplemental oxygen.
Hospitalized, on non-invasive ventilation or high flow oxygen devices.
Hospitalized, on invasive mechanical ventilation or ECMO.
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to category 5, 6 or 7 of the ordinal scale</measure>
    <time_frame>29 days</time_frame>
    <description>Time to change from baseline category to worsening into 5,6 or 7 categories of the ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause at 15 days</measure>
    <time_frame>15 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause at 29 days</measure>
    <time_frame>29 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation free days</measure>
    <time_frame>29 days</time_frame>
    <description>days free from oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>29 days</time_frame>
    <description>days free from mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>29 days</time_frame>
    <description>Infusion-related adverse events Cumulative incidence of serious adverse events (SAEs) Cumulative incidence of Grade 3 and 4 adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies levels in CP donors recovered from COVID-19</measure>
    <time_frame>3 months</time_frame>
    <description>Quantitative total antibodies and neutralizing antibody activity against SARSCoV-2 in the sera from donors and patients using viral pseudotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>Days 1,3,5,8,11 and 29</time_frame>
    <description>Change in PCR for SARS-CoV-2 in naso/oropharyngeal swabs and blood at baseline and on days 3, 5, 8, 11 (while hospitalized); and days 15 and 29 (if able to return to clinic or still hospitalized).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in biological parameters</measure>
    <time_frame>Days 1,3,5,8,11 and 29</time_frame>
    <description>Serum levels of CRP, lymphocyte count, LDH, D Dimer,IL-6, coagulation tests at baseline and days 3, 5, 8, 11, 15 and 29.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care (SOC) for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and derivatives.</intervention_name>
    <description>Administration of fresh plasma from donor immunized against COVID-19</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Convalescent Plasma from patients recovered from COVID-19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care for the treatment of COVID-19 in hospitalized patients</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent prior to performing study procedures. Witnessed oral consent
             will be accepted in order to avoid paper handling. Written consent by patient or
             representatives will be obtained as soon as possible.

          2. Male or female adult patient ≥18 years of age at time of enrolment.

          3. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR in
             naso/oropharyngeal swabs or any other relevant specimen.

          4. Patients requiring hospitalization for COVID-19 without mechanical ventilation
             (invasive or non-invasive) or high flow oxygen devices and at least one of the
             following:

               -  Radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, CT scan,
                  etc.), OR

               -  Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤ 94% on room
                  air that requires supplemental oxygen.

          5. No more than 12 days between the onset of symptoms (fever or cough) and treatment
             administration day.

        Exclusion Criteria:

          1. Requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen
             devices.

          2. More than 12 days since symptoms (fever or cough).

          3. Participation in any other clinical trial of an experimental treatment for COVID-19.

          4. In the opinion of the clinical team, progression to death is imminent and inevitable
             within the next 24 hours, irrespective of the provision of treatments.

          5. Any incompatibility or allergy to the administration of human plasma.

          6. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt;30).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Avendaño Solá, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Duarte Palomino, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Ramos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Bueno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inmaculada Casas Flecha, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Nacional de Microbiología, Instituto de Salud Carlos III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Avendaño Solá, MD, PhD</last_name>
    <phone>+34 91 191 64 79</phone>
    <email>cavendano@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Ramón Paño Pardo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>José Ramón Paño Pardo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Moreno Chulilla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Cervero Jiménez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Cervero Jiménez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Barberana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Muñez, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Muñez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Luis Bueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Meco</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Hernández Guitiérrez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Hernández Gutiérrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Flores Ballester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio de Santos Gil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio de Santos Gil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Vicuña Andrés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Machado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marina Machado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Anguita Velasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Martínez Sanz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Martínez Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicente Estrada Pérez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Estrada Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Isabel Saez Serrano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Lora Tamayo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaime Lora Tamayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Liz Paciello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Avendaño Solá</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Convalescent Plasma</keyword>
  <keyword>SOC</keyword>
  <keyword>CP</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

